Skip to main content
Top
Published in: International Journal of Colorectal Disease 8/2018

01-08-2018 | Original Article

Real-world study of a novel prognostic scoring system: for a more precise prognostication and better clinical treatment guidance in stages II and III colon cancer

Authors: Qi Liu, Yanlei Ma, Dakui Luo, Sanjun Cai, Qingguo Li, Xinxiang Li

Published in: International Journal of Colorectal Disease | Issue 8/2018

Login to get access

Abstract

Purpose

This study aimed to improve the American Joint Committee on Cancer (AJCC) Tumor Node Metastases (TNM) staging system and demonstrate the improvement in prognostic accuracy and clinical management guidance in colon cancer using the novel prognostic score (P score).

Methods

Eligible patients were identified using the Surveillance, Epidemiology, and End Results database. A P score (based on age, tumor size, and tumor grade) was assigned to each patient. The Cox proportional hazards regression analyses were performed to identify independent factors associated with prognosis. The Kaplan–Meier survival curves were used to analyze the prognosis of patients with colon cancer with different P scores. The TNM staging system was compared with the P score in stages I–IV by calculating the concordance index.

Results

The multivariate Cox analysis indicated that a higher P score was independently associated with a higher risk of cancer-specific mortality. The Kaplan–Meier survival curves showed that the survival benefit gradually increased as the P score decreased. The concordance index rose from 0.5, 0.593, 0.633, and 0.551 of AJCC TNM staging system to 0.709, 0.651, 0.691, and 0.623 of P score in stages I–IV, respectively.

Conclusions

The P score was an independent prognostic factor of colon cancer and had a much better prognostic accuracy than the AJCC TNM staging system in all patients with colon cancer. It may help in identifying patients with high-risk stage II colon cancer who were candidates for adjuvant therapy and differentiating patients with stage III colon cancer for adjuvant therapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Siegel RL et al (1900) Colorectal cancer statistics, 2017. CA Cancer J Clin 64(2):104–117CrossRef Siegel RL et al (1900) Colorectal cancer statistics, 2017. CA Cancer J Clin 64(2):104–117CrossRef
2.
go back to reference Weiser MR et al (2011) Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. J Clin Oncol Off J Am Soc Clin Oncol 29(36):4796–4802CrossRef Weiser MR et al (2011) Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. J Clin Oncol Off J Am Soc Clin Oncol 29(36):4796–4802CrossRef
4.
go back to reference Auclin E et al (2017) Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. Ann Oncol Off J Euro Soc Med Oncol 28(5):mdx030CrossRef Auclin E et al (2017) Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. Ann Oncol Off J Euro Soc Med Oncol 28(5):mdx030CrossRef
5.
go back to reference Kune GA et al (1990) Survival in patients with large-bowel cancer. A population-based investigation from the Melbourne Colorectal Cancer Study. Dis Colon Rectum 33(11):938CrossRefPubMed Kune GA et al (1990) Survival in patients with large-bowel cancer. A population-based investigation from the Melbourne Colorectal Cancer Study. Dis Colon Rectum 33(11):938CrossRefPubMed
6.
go back to reference Aquina CT, Mohile SG, Tejani MA, Becerra AZ, Xu Z, Hensley BJ, Arsalani-Zadeh R, Boscoe FP, Schymura MJ, Noyes K, Monson JRT, Fleming FJ (2017) The impact of age on complications, survival, and cause of death following colon cancer surgery. Br J Cancer 116:389–397CrossRefPubMedPubMedCentral Aquina CT, Mohile SG, Tejani MA, Becerra AZ, Xu Z, Hensley BJ, Arsalani-Zadeh R, Boscoe FP, Schymura MJ, Noyes K, Monson JRT, Fleming FJ (2017) The impact of age on complications, survival, and cause of death following colon cancer surgery. Br J Cancer 116:389–397CrossRefPubMedPubMedCentral
7.
8.
go back to reference Patel SS et al (2013) Elderly patients with colon cancer have unique tumor characteristics and poor survival. Cancer 119(4):739CrossRefPubMed Patel SS et al (2013) Elderly patients with colon cancer have unique tumor characteristics and poor survival. Cancer 119(4):739CrossRefPubMed
9.
go back to reference Yamano T et al (2017) Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: a retrospective multicentre study. Eur J Cancer 81:90CrossRefPubMed Yamano T et al (2017) Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: a retrospective multicentre study. Eur J Cancer 81:90CrossRefPubMed
10.
go back to reference Li Q et al (2014) Better long-term survival in young patients with non-metastatic colorectal cancer after surgery, an analysis of 69,835 patients in SEER database. Plos One 9(4):e93756CrossRefPubMedPubMedCentral Li Q et al (2014) Better long-term survival in young patients with non-metastatic colorectal cancer after surgery, an analysis of 69,835 patients in SEER database. Plos One 9(4):e93756CrossRefPubMedPubMedCentral
11.
go back to reference Cerottini JP et al (1999) Prognostic factors in colorectal cancer. Oncol Rep 6(2):409–414PubMed Cerottini JP et al (1999) Prognostic factors in colorectal cancer. Oncol Rep 6(2):409–414PubMed
12.
go back to reference Phillips MRKS et al (1984) Large bowel cancer: surgical pathology and its relationship to survival. Br J Surg 71(8):604CrossRefPubMed Phillips MRKS et al (1984) Large bowel cancer: surgical pathology and its relationship to survival. Br J Surg 71(8):604CrossRefPubMed
13.
go back to reference Gill S et al (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol Off J Am Soc Clin Oncol 22(10):1797CrossRef Gill S et al (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol Off J Am Soc Clin Oncol 22(10):1797CrossRef
14.
go back to reference Kornprat P et al (2011) Value of tumor size as a prognostic variable in colorectal cancer: a critical reappraisal. Am J Clin Oncol 34(1):43CrossRefPubMed Kornprat P et al (2011) Value of tumor size as a prognostic variable in colorectal cancer: a critical reappraisal. Am J Clin Oncol 34(1):43CrossRefPubMed
15.
go back to reference Saha S et al. (2012) Tumor size as a prognostic factor for patients with colon cancer undergoing sentinel lymph node mapping and conventional surgery. Ann Surg Oncol. 20(4): p. - Saha S et al. (2012) Tumor size as a prognostic factor for patients with colon cancer undergoing sentinel lymph node mapping and conventional surgery. Ann Surg Oncol. 20(4): p. -
16.
go back to reference Saha S et al (2015) Tumor size predicts long-term survival in colon cancer: an analysis of the National Cancer Data Base. Am J Surg 209(3):570CrossRefPubMed Saha S et al (2015) Tumor size predicts long-term survival in colon cancer: an analysis of the National Cancer Data Base. Am J Surg 209(3):570CrossRefPubMed
17.
18.
go back to reference Manilich EA et al (2011) A novel data-driven prognostic model for staging of colorectal cancer. J Am Coll Surg 213(5):579–588.e2CrossRefPubMed Manilich EA et al (2011) A novel data-driven prognostic model for staging of colorectal cancer. J Am Coll Surg 213(5):579–588.e2CrossRefPubMed
19.
go back to reference Renfro LA, Grothey A, Xue Y, Saltz LB, André T, Twelves C, Labianca R, Allegra CJ, Alberts SR, Loprinzi CL, Yothers G, Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) Group (2014) ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. J Natl Cancer Inst 106(12):dju333CrossRefPubMedPubMedCentral Renfro LA, Grothey A, Xue Y, Saltz LB, André T, Twelves C, Labianca R, Allegra CJ, Alberts SR, Loprinzi CL, Yothers G, Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) Group (2014) ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. J Natl Cancer Inst 106(12):dju333CrossRefPubMedPubMedCentral
20.
go back to reference Benson AB et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol Off J Am Soc Clin Oncol 22(16):3408CrossRef Benson AB et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol Off J Am Soc Clin Oncol 22(16):3408CrossRef
21.
22.
go back to reference O'Connor ES et al (2011) Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol Off J Am Soc Clin Oncol 29(25):3381–3388CrossRef O'Connor ES et al (2011) Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol Off J Am Soc Clin Oncol 29(25):3381–3388CrossRef
23.
go back to reference Verhoeff SR et al (2016) Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer. Int J Cancer 139(1):187–193CrossRefPubMed Verhoeff SR et al (2016) Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer. Int J Cancer 139(1):187–193CrossRefPubMed
24.
go back to reference Benson AB et al (2011) NCCN clinical practice guidelines in oncology: colon cancer version 1:2012. J Natl Compr Cancer Netw 9(11):1238–1290CrossRef Benson AB et al (2011) NCCN clinical practice guidelines in oncology: colon cancer version 1:2012. J Natl Compr Cancer Netw 9(11):1238–1290CrossRef
25.
go back to reference Labianca R et al (2013) Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Euro Soc Med Oncol 24(Suppl 6(3)):vi64 Labianca R et al (2013) Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Euro Soc Med Oncol 24(Suppl 6(3)):vi64
26.
go back to reference Chau I et al (2005) A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol Off J Euro Soc Med Oncol 16(4):549CrossRef Chau I et al (2005) A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol Off J Euro Soc Med Oncol 16(4):549CrossRef
27.
go back to reference Lonardi S et al (2016) Phase III trial comparing 3 to 6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. Ann Oncol Off J Euro Soc Med Oncol 27(11):mdw404 Lonardi S et al (2016) Phase III trial comparing 3 to 6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. Ann Oncol Off J Euro Soc Med Oncol 27(11):mdw404
28.
go back to reference Cramptom P, Williams R (2009) Adjuvant chemotherapy for stage II colon cancer: the role of molecular markers in choosing therapy. Gastrointest Cancer Res 3(5):191–196 Cramptom P, Williams R (2009) Adjuvant chemotherapy for stage II colon cancer: the role of molecular markers in choosing therapy. Gastrointest Cancer Res 3(5):191–196
29.
go back to reference Clarklangone KM et al (2010) Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX® Colon Cancer Assay. BMC Cancer 10(1):691CrossRef Clarklangone KM et al (2010) Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX® Colon Cancer Assay. BMC Cancer 10(1):691CrossRef
30.
go back to reference Roth AD et al (2012) Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 104(21):1635CrossRefPubMed Roth AD et al (2012) Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 104(21):1635CrossRefPubMed
31.
go back to reference Kwon KA et al (2010) Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer 10(1):203–203CrossRefPubMedPubMedCentral Kwon KA et al (2010) Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer 10(1):203–203CrossRefPubMedPubMedCentral
32.
go back to reference Romanus D et al (2009) Concordance with NCCN colorectal cancer guidelines and ASCO/NCCN quality measures: an NCCN institutional analysis. J Natl Compr Cancer Netw 7(8):895–904CrossRef Romanus D et al (2009) Concordance with NCCN colorectal cancer guidelines and ASCO/NCCN quality measures: an NCCN institutional analysis. J Natl Compr Cancer Netw 7(8):895–904CrossRef
Metadata
Title
Real-world study of a novel prognostic scoring system: for a more precise prognostication and better clinical treatment guidance in stages II and III colon cancer
Authors
Qi Liu
Yanlei Ma
Dakui Luo
Sanjun Cai
Qingguo Li
Xinxiang Li
Publication date
01-08-2018
Publisher
Springer Berlin Heidelberg
Published in
International Journal of Colorectal Disease / Issue 8/2018
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-018-3071-1

Other articles of this Issue 8/2018

International Journal of Colorectal Disease 8/2018 Go to the issue